11 月 18, 2026

漢康生技榮獲115年度「國家藥物科技研究發展獎」銀質獎 HCB101創新免疫治療研發成果獲國家級肯定 HanchorBio Receives Silver Award at the 2026 National Pharmaceutical Technology and Research Development Award, Recognizing HCB101’s Innovative Immunotherapy Development

HanchorBio Receives Silver Award at the 2026 National Pharmaceutical Technology and Research Development Award, Recognizing HCB101’s Innovative Immunotherapy Development

HCB101’s differentiated macrophage-directed immunotherapy mechanism bridges innate and adaptive immune responses, highlighting its potential in next-generation cancer immunotherapy and clinical development

 

[Taipei, Shanghai, San Francisco | November 18, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, announced that its proprietary investigational immunotherapy candidate HCB101 has received the Silver Award at the 2026 National Pharmaceutical Technology and Research Development Award (NPRDA), jointly organized by Taiwan’s Ministry of Health and Welfare and Ministry of Economic Affairs. The recognition highlights HanchorBio’s achievements in innovative drug development, differentiated mechanisms of action, and clinical translational research. The award ceremony was held at the National Biotechnology Research Park in Taipei, Taiwan.

The National Pharmaceutical Technology and Research Development Award is one of Taiwan’s prominent national awards recognizing innovation in pharmaceutical research, drug development, and related manufacturing technologies, with the aim of advancing domestic pharmaceutical innovation and industry development. HCB101’s recognition underscores HanchorBio’s long-term commitment to proprietary drug discovery and development, its differentiated research strategy centered on macrophage-directed immunotherapy, and the Company’s potential to further expand its presence in the global cancer immunotherapy landscape.

 

“Receiving the award for HCB101 is an important recognition of HanchorBio’s research and development capabilities and our team’s commitment to innovative drug development,” said Dr. Scott Liu, Chairman and Chief Executive Officer of HanchorBio. “We believe the future of cancer immunotherapy should not be limited to targeting a single immune pathway, but should instead involve more comprehensive activation of both the innate and adaptive immune systems. By targeting macrophage-mediated immune mechanisms, HCB101 is designed to promote tumor cell phagocytosis and antigen presentation, potentially enabling broader and more durable antitumor immune responses. This approach reflects our continued commitment to advancing the FBDB™ platform and exploring the next generation of immunotherapies.”

 

HCB101 Differentiates Itself Through Macrophage-Directed Immunotherapy

Current cancer immunotherapies are predominantly focused on T cell-directed approaches, including PD-1/PD-L1 immune checkpoint inhibitors, CAR-T cell therapies, and T cell-engaging antibodies. However, some patients do not achieve optimal therapeutic responses due to insufficient tumor antigen presentation, inadequate populations of tumor-reactive T cells, or immunosuppressive factors within the tumor microenvironment. These limitations highlight the significant unmet medical needs that remain in cancer immunotherapy.

Unlike conventional T cell-directed immunotherapies, HCB101 was designed using HanchorBio’s proprietary FBDB™ platform to target macrophages and the myeloid immune system. By blocking the CD47-SIRPα “don’t-eat-me” signaling pathway, HCB101 is designed to enhance macrophage recognition and phagocytosis of tumor cells, thereby increasing tumor antigen processing and presentation and creating favorable conditions for subsequent T cell-mediated immune responses.

HCB101’s core differentiation extends beyond enhancing macrophage-mediated tumor cell phagocytosis. Through sustained antigen presentation, HCB101 has the potential to promote the de novo formation of tumor-reactive T cell clones, expansion of existing T cell clones, and development of immunological memory. By connecting innate and adaptive immunity, this mechanism may broaden and sustain antitumor immune responses.

Compared with conventional immune checkpoint inhibitors, which primarily act by relieving inhibitory signals on T cells, HCB101 represents a distinct therapeutic strategy that targets earlier stages of immune activation, offering potential complementary and combination treatment opportunities with existing immunotherapies.

 

HCB101 Clinical Progress Supports Global Development Strategy

HanchorBio’s preclinical studies have shown that, in addition to enhancing tumor cell phagocytosis, HCB101 is associated with increased antigen-presenting cells, enhanced T cell infiltration and activation, and improvements in the tumor immune microenvironment. These findings provide scientific support for its proposed mechanism of bridging innate and adaptive immune responses.

In clinical development, HCB101 has demonstrated preliminary antitumor activity across multiple solid tumor studies. According to recent clinical data in second-line gastric cancer and gastroesophageal junction cancer, HCB101-based combination therapy achieved an objective response rate (ORR) of 62.5% at intermediate doses (5–8 mg/kg), compared with an ORR of approximately 28% reported for standard-of-care treatment, along with a disease control rate (DCR) of 100%.

In second-line microsatellite-stable (MSS) colorectal cancer, tumor responses and disease control have also been observed across different combination regimens, supporting further clinical investigation. These findings remain preliminary and require validation in larger clinical trials.

HanchorBio continues to advance HCB101’s global clinical development strategy. Through ongoing interactions with the U.S. Food and Drug Administration (FDA) and other regulatory authorities, the Company is planning future pivotal clinical trials to further evaluate HCB101’s clinical potential across different solid tumor indications.

 

Advancing Global Clinical Development and International Collaborations to Expand the Innovative Immunotherapy Pipeline

In addition to advancing clinical studies of HCB101 in gastric cancer, colorectal cancer, and head and neck cancer, HanchorBio will continue integrating biomarker analyses and translational research to deepen its understanding of macrophage-directed immune mechanisms and explore development opportunities across additional tumor types and combination treatment strategies.

The Company is also leveraging its proprietary FBDB™ platform to expand its portfolio of multifunctional immunotherapies. By integrating in-house research and development, global clinical development, and collaborations with international pharmaceutical companies, HanchorBio aims to advance the clinical and commercial development of innovative therapeutics.

Receiving the Silver Award at the National Pharmaceutical Technology and Research Development Award not only recognizes HCB101’s research and development achievements, but also reinforces HanchorBio’s commitment to deepening international research collaborations and advancing the next generation of cancer immunotherapies.

 

 

About HanchorBio

HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company pioneering next-generation immuno-oncology therapies through its proprietary Fc-Based Designer Biologics (FBDB™) platform. By combining multi-axis targeting with tuned immune effector engagement, HanchorBio develops breakthrough therapeutics that overcome tumor resistance mechanisms across innate and adaptive pathways. Operating across Taipei, the San Francisco Bay Area, and Shanghai, HanchorBio is advancing a clinical and preclinical pipeline spanning multi-functional fusion proteins for hard-to-treat solid tumors and autoimmune disorders. For more information, visit: www.HanchorBio.com.

 

Forward-Looking Statements

This press release contains forward-looking statements regarding HanchorBio’s investigational products, proprietary technologies, clinical development programs, potential therapeutic applications, and future combination strategies. These statements involve scientific, clinical, regulatory, operational, and commercial risks and uncertainties. Preliminary clinical and preclinical findings may not predict future outcomes, and adequately controlled clinical trials have not established the safety, efficacy, and incremental clinical benefit of HanchorBio’s investigational therapies. Actual results and future development activities may differ materially from current expectations. Except as required by applicable law, HanchorBio undertakes no obligation to update or revise these statements.

 

HanchorBio Business Development Contact:

Email: [email protected]

Investor & Media Contact:

Email: [email protected]

 

漢康生技榮獲115年度「國家藥物科技研究發展獎」銀質獎 HCB101創新免疫治療研發成果獲國家級肯定

HCB101以獨特巨噬細胞導向免疫機制,串聯先天與後天免疫反應,展現新一代癌症免疫治療差異化優勢與臨床開發潛力

【台北、上海、舊金山,2026年11月18日】-全球臨床階段生技公司漢康生技(TWSE:7827)宣布,公司自主研發的創新癌症免疫治療候選藥物HCB101,榮獲衛生福利部與經濟部共同主辦的115年度「國家藥物科技研究發展獎」銀質獎,展現漢康生技在創新藥物研發、獨特作用機制及臨床轉譯研究上的成果,獲得國家級肯定。頒獎典禮於台北國家生技研究園區舉行。

「國家藥物科技研究發展獎」為台灣具代表性的國家級藥物研發獎項,旨在表揚新藥物及相關產製技術的創新研發成果,促進國內新藥研發與產業發展。此次HCB101獲獎,不僅肯定漢康生技長期投入自主創新藥物研發的成果,也凸顯其以巨噬細胞導向免疫治療為核心的差異化研發策略,以及在全球癌症免疫治療領域持續拓展的發展潛力。

漢康生技董事長暨執行長劉世高博士表示:「此次HCB101榮獲國家藥物科技研究發展獎銀質獎,是對漢康生技自主研發能力及團隊長期投入創新藥物開發的重要肯定。我們相信,癌症免疫治療的未來不應侷限於單一免疫路徑,而是需要更全面地調動先天與後天免疫系統。HCB101從巨噬細胞導向免疫機制切入,透過促進腫瘤細胞吞噬與抗原呈現,為建立更廣泛且持久的抗腫瘤免疫反應提供新的可能性。這也是我們持續發展FBDB™平台、探索新一代免疫治療的重要方向。」

 

HCB101以巨噬細胞導向免疫機制建立差異化優勢

目前全球癌症免疫治療主要以T細胞導向策略為主,包括PD-1/PD-L1免疫檢查點抑制劑、CAR-T細胞療法及T細胞銜接抗體等。然而,部分患者因腫瘤抗原呈現不足、缺乏足夠的腫瘤反應性T細胞,或受到腫瘤微環境免疫抑制等因素影響,無法獲得理想治療反應,顯示現有免疫療法仍存在未被滿足的醫療需求。

有別於傳統以T細胞為核心的免疫治療,HCB101透過漢康生技自主開發的FBDB™(Fc-Based Designer Biologics)平台設計,從巨噬細胞及髓系免疫系統切入,藉由阻斷CD47-SIRPα「不要吃我」(don’t-eat-me)訊號,促進巨噬細胞辨識並吞噬腫瘤細胞,進一步增加腫瘤抗原的處理與呈現,為後續T細胞免疫反應創造有利條件。

HCB101的核心差異化優勢,不僅在於促進巨噬細胞吞噬腫瘤細胞,更在於其有潛力透過持續性的抗原呈現,促進新的腫瘤反應性T細胞克隆形成、既有T細胞克隆擴增,以及免疫記憶建立,從先天免疫延伸至後天免疫,進一步擴大並延續抗腫瘤免疫反應。相較於主要透過解除T細胞抑制訊號發揮作用的傳統免疫檢查點抑制劑,HCB101提供了從免疫反應前端切入的不同治療策略,具有與現有免疫療法形成互補及聯合治療的開發潛力。

 

HCB101臨床進展支持全球開發策略

漢康生技的臨床前研究顯示,HCB101除可促進腫瘤細胞吞噬外,亦觀察到抗原呈現細胞增加、T細胞浸潤與活化提升,以及腫瘤免疫微環境改善等現象,為其連結先天免疫與後天免疫的作用機制提供科學支持。

在臨床開發方面,HCB101已於多項實體腫瘤研究中觀察到初步抗腫瘤活性。根據近期二線胃癌及胃食道交界部癌臨床研究數據,HCB101聯合治療的中劑量(5~8mg/kg)的客觀緩解率(ORR)達62.5%(對比標準療法ORR 28%),疾病控制率(DCR)達100%;在二線微衛星穩定型(MSS)大腸直腸癌研究中,亦於不同聯合治療方案觀察到腫瘤緩解及疾病控制,支持後續臨床研究。相關結果仍屬早期臨床資料,須透過更大規模試驗進一步驗證。

此外,漢康生技正持續推進HCB101全球臨床開發布局,並透過與美國食品藥物管理局(FDA)及其他監管機構的溝通,規劃後續關鍵性臨床試驗策略,期望進一步驗證HCB101在不同實體腫瘤中的臨床應用潛力。

 

深化全球臨床開發與國際合作 拓展創新免疫治療布局

除持續推進HCB101於胃癌、大腸直腸癌及頭頸癌等適應症的臨床研究外,漢康生技亦將結合生物標記分析及轉譯研究,深化對巨噬細胞導向免疫機制的理解,探索不同腫瘤類型及聯合治療策略的開發機會。

同時,公司持續運用FBDB™平台拓展多功能免疫治療產品布局,並結合自主研發、全球臨床開發及國際藥廠合作,推進創新藥物的臨床與商業化發展。此次榮獲國家藥物科技研究發展獎銀質獎,不僅是對HCB101研發成果的肯定,也為漢康生技持續深化國際研發合作、推動新一代免疫治療發展增添動能。

 

 

關於漢康生技

漢康生技(TWSE:7827)為全球臨床階段生技公司,透過專有的 Fc-Based Designer Biologics(FBDB™)平台,致力於開發新一代腫瘤免疫療法。藉由整合多重免疫路徑標靶及精準調控免疫效應功能,漢康生技開發創新療法,以克服腫瘤在先天性與適應性免疫路徑中的抗藥機制。

漢康生技於台北、美國舊金山灣區及上海設有營運據點,持續推進臨床及臨床前產品管線,開發針對難治型實體腫瘤及自體免疫疾病的多功能融合蛋白療法。

 

前瞻性聲明

本新聞稿包含有關漢康生技研究中產品、專有技術、臨床開發計畫、潛在治療應用及未來聯合治療策略之前瞻性聲明。此類聲明涉及科學、臨床、法規、營運及商業等方面的風險與不確定性。

初步臨床及臨床前研究結果未必能預測未來成果,且漢康生技研究中療法的安全性、有效性及額外臨床效益,尚未經充分對照的臨床試驗確立。實際結果及未來研發活動可能與目前預期存在重大差異。除適用法律另有規定外,漢康生技不承擔更新或修訂此類聲明的義務。

 

11 月 16, 2026
致漢康生技全體股東的一封信
致漢康生技全體股東的一封信   親愛的股東朋友們,大家好: 漢康生技一路走來,我與團隊多年來全心投入 […]
11 月 18, 2026
漢康生技 HCB301 臨床進展說明
漢康生技 HCB301 臨床進展說明:與 FDA 共同重視病患安全,積極優化臨床方案,持續展現創新免疫療法潛力 […]